Bicycle Therapeutics plc

NasdaqGS:BCYC Voorraadrapport

Marktkapitalisatie: US$1.4b

Bicycle Therapeutics Beheer

Beheer criteriumcontroles 4/4

De CEO Bicycle Therapeutics is Kevin Lee, benoemd in Sep2015, heeft een ambtstermijn van 9.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.54M, bestaande uit 12.8% salaris en 87.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.37% van de aandelen van het bedrijf, ter waarde $ 5.26M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 5.3 jaar.

Belangrijke informatie

Kevin Lee

Algemeen directeur

US$5.5m

Totale compensatie

Percentage CEO-salaris12.8%
Dienstverband CEO9.2yrs
Eigendom CEO0.4%
Management gemiddelde ambtstermijn2.8yrs
Gemiddelde ambtstermijn bestuur5.3yrs

Recente managementupdates

Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why

May 10
Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why

Recent updates

Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern

Nov 07

Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Nov 03
Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Oct 23
Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Bicycle Therapeutics Is Looking Increasingly Attractive

Aug 20

Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert

May 24

Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why

May 10
Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why

Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher

May 04
Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher

Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?

Apr 19
Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?

Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point

Mar 12

Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely

Jan 04
Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely

Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts

Nov 07
Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts

The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts

May 14
The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts

Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%

Mar 31
Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%

Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?

Mar 09
Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?

Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Nov 08
Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Bicycle Therapeutics: Exploring An Intriguing Developmental Platform

Oct 08

Bicycle Therapeutics initiated Outperform at Cowen citing drug platform

Aug 31

Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration

Jul 12

Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?

Jul 10
Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?

Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer

Jul 05

Bicycle Therapeutics: Trying To Catch This Falling Knife

Apr 17

Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Apr 11
Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Bicycle Therapeutics: A Buy Ahead Of AACR Presentation

Mar 25

Bicycle Therapeutics: An Oncology Play With Big Potential

Feb 28

Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?

Nov 07
Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?

Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles

Aug 25

The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically

Aug 07
The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically

News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts

May 08
News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts

Analyse CEO-vergoeding

Hoe is Kevin Lee's beloning veranderd ten opzichte van Bicycle Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$166m

Jun 30 2024n/an/a

-US$165m

Mar 31 2024n/an/a

-US$168m

Dec 31 2023US$6mUS$710k

-US$181m

Sep 30 2023n/an/a

-US$162m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$124m

Dec 31 2022US$9mUS$673k

-US$113m

Sep 30 2022n/an/a

-US$101m

Jun 30 2022n/an/a

-US$87m

Mar 31 2022n/an/a

-US$78m

Dec 31 2021US$4mUS$677k

-US$67m

Sep 30 2021n/an/a

-US$66m

Jun 30 2021n/an/a

-US$62m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$3mUS$592k

-US$51m

Sep 30 2020n/an/a

-US$38m

Jun 30 2020n/an/a

-US$37m

Mar 31 2020n/an/a

-US$35m

Dec 31 2019US$4mUS$517k

-US$31m

Sep 30 2019n/an/a

-US$33m

Jun 30 2019n/an/a

-US$31m

Mar 31 2019n/an/a

-US$26m

Dec 31 2018US$818kUS$386k

-US$22m

Compensatie versus markt: De totale vergoeding ($USD 5.54M ) Kevin } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: De vergoeding van Kevin is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Kevin Lee (56 yo)

9.2yrs

Tenure

US$5,540,400

Compensatie

Dr. Kevin Lee, M.B.A., Ph D., has been Chief Executive Officer of Bicycle Therapeutics plc since September 2015. Dr. Lee joined Bicycle Therapeutics from Pfizer where he served as Senior Vice President and...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Kevin Lee
CEO & Executive Director9.2yrsUS$5.54m0.37%
$ 5.3m
Gregory Winter
Co-Founder & Non-Executive Directorno dataUS$477.04k0.24%
$ 3.4m
Alethia Young
Chief Financial Officer1.3yrsUS$2.88mgeen gegevens
Santiago Arroyo
Chief Development Officer1.7yrsUS$2.82m0%
$ 0
Christian Heinis
Scientific Founderno datageen gegevensgeen gegevens
Alistair Milnes
Chief Operating Officer2.8yrsUS$5.98m0.024%
$ 344.5k
Travis Thompson
Senior VP1.4yrsgeen gegevens0%
$ 0
Michael Skynner
Chief Technology Officer2.8yrsUS$3.07m0.073%
$ 1.0m
Stephanie Yao
Senior Vice President of Investor Relations and Corporate Communicationsno datageen gegevensgeen gegevens
Zafar Qadir
Chief Legal Officer & General Counsel4.6yrsgeen gegevensgeen gegevens
Gillian Langford
Head of Clinical and Project Management8.5yrsgeen gegevensgeen gegevens
Phil Jeffrey
Senior VP of Pre-Clinical Development6yrsgeen gegevensgeen gegevens

2.8yrs

Gemiddelde duur

55.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BCYC wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Kevin Lee
CEO & Executive Director9.2yrsUS$5.54m0.37%
$ 5.3m
Gregory Winter
Co-Founder & Non-Executive Directorno dataUS$477.04k0.24%
$ 3.4m
Keith Peters
Chairman of Scientific Advisory Board6.5yrsgeen gegevensgeen gegevens
Pierre Legault
Non-Executive Chairman5.7yrsUS$1.06m0.031%
$ 441.6k
Jose-Carlos Gutierrez-Ramos
Independent Non-Executive Director3.7yrsUS$482.29k0.016%
$ 220.8k
Richard Kender
Independent Non-Executive Director5.3yrsUS$526.91k0.016%
$ 220.8k
Garret FitzGerald
Member of Scientific Advisory Board4.1yrsgeen gegevensgeen gegevens
Caetano Reis e Sousa
Member of Scientific Advisory Board4.1yrsgeen gegevensgeen gegevens
Janice Bourque
Independent Non-Executive Director5.3yrsUS$495.41k0.016%
$ 220.8k
Geoffrey Shapiro
Member of Scientific Advisory Board6.5yrsgeen gegevensgeen gegevens
Charles Swanton
Member of Scientific Advisory Board4.1yrsgeen gegevensgeen gegevens
Jane Grogan
Member of Scientific Advisory Board4.1yrsgeen gegevensgeen gegevens

5.3yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BCYC wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).